close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.38 +0.34 (+1.36%)
Streaming Delayed Price Updated: 2:36 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Pfizer Stock On-Track For Worst Day In Over 8 Months As BofA Flags Faster Covid-19 Product Erosion ↗
The company now expects full year 2025 guidance of about $62 billion, to the lower end of its previous guidance of $61 to $64 billion and below an analyst estimate of $62.52 billion. 
Via Stocktwits
News headline image
These S&P500 stocks are moving in today's session ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Deep Dive: Windlas Biotech Limited – A Pharmaceutical Growth Story
As of December 16, 2025, Windlas Biotech Limited (NSE: WINDLAS, BSE: 543403) stands as a significant player in India's burgeoning pharmaceutical sector, primarily recognized for its robust contract... 
Via PredictStreet
Topics Initial Public Offering
News headline image
Pfizer Shares Fall As 2026 Outlook Reflects Weaker COVID-19 Drug Demand ↗
Pfizer shares fell after the company issued weaker-than-expected 2026 guidance, citing lower demand for COVID-19 products and upcoming patent expirations. 
Via Talk Markets
Topics Intellectual Property
News headline image
These S&P500 stocks are gapping in today's session ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise' ↗
Pfizer issued a light outlook for 2026 on Tuesday, missing Wall Street's earnings forecast following a suite of acquisitions. 
Via Investor's Business Daily
News headline image
Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts ↗
Pfizer previews 2026 guidance with earnings below consensus, softer sales outlook, COVID decline and LOE headwinds offset by pipeline growth. 
Via Benzinga
News headline image
Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗
Via MarketBeat
News headline image
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
From Pfizer Inc.
Via Business Wire
News headline image
Where Will Eli Lilly Be in 10 Years? ↗
In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today. 
Via The Motley Fool
Topics Intellectual Property
News headline image
These S&P500 stocks are the most active in today's session ↗
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
News headline image
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst ↗
Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating. 
Via Benzinga
Topics Intellectual Property
News headline image
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Will Dogecoin Reach $1 By the End of the Year? ↗
Dogecoin's price would need to rise more than seven-fold before the calendar turns to 2026. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗
Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Teladoc and Buy This Healthcare Stock Instead ↗
It's time for investors to give up on the telemedicine leader. 
Via The Motley Fool
News headline image
Rigani Press Announces Barnes & Noble Book Signing for Dr. S. Yin Ho's Groundbreaking Book
Via PRLog
Topics Artificial Intelligence
News headline image
Pfizer Declares First-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. ↗
Keep your expectations in check. 
Via The Motley Fool
News headline image
The Best Turnaround Stock to Invest $1,000 in Right Now ↗
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term. 
Via The Motley Fool
News headline image
Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Great Divergence: Investors Retreat from High-Flying Tech as Market Seeks New Equilibrium
The financial markets are witnessing a significant "Great Divergence" as investor sentiment pivots sharply away from the high-flying technology stocks that have dominated portfolios for years. As of... 
Via MarketMinute
Topics Artificial Intelligence Economy Law Enforcement
News headline image
Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? ↗
Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings. 
Via Stocktwits
Topics Artificial Intelligence Stocks
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer&#39;s Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer ↗
Pfizer reports Phase 3 results showing Tukysa with trastuzumab and pertuzumab prolonged progression-free survival by 8.6 months in HER2+ metastatic breast cancer. 
Via Benzinga
News headline image
Markets Brace for Anticipated Fed Rate Cut Amidst Shifting Economic Landscape
As December 2025 draws to a close, financial markets are holding their breath in anticipation of a pivotal Federal Reserve interest rate decision. Investopedia's analysis reveals a pervasive market... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
News headline image
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Down 50%, Should You Buy the Dip on Pfizer? ↗
Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Looking for the most active stocks in the S&P500 index on Tuesday? ↗
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today